In summary, these results show that the antitumor effects of the combination of effective low-dose Anlotinib and anti-PD-1 therapy are partially mediated by CD8+ T cells while Anlotinib treatments inhibit tumor growth independent of IFN-γ. This evidence concerns the gene CD8A and neoplasm.